<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02999945</url>
  </required_header>
  <id_info>
    <org_study_id>OPTIGROW</org_study_id>
    <nct_id>NCT02999945</nct_id>
  </id_info>
  <brief_title>Optimal Growth of Preterm Infants With Growth Restriction</brief_title>
  <acronym>OPTIGROW</acronym>
  <official_title>Body Composition, Metabolic Programming and Long Term Outcome of Growth Restricted Preterm Infants Under Different Nutritional Management A Prospective Randomized Controlled Multicenter Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of Vienna</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Medical University of Graz</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ludwig-Maximilians - University of Munich</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital Tuebingen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Erlangen-Nürnberg Medical School</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Milan</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Poznan University of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Lund University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Medical University of Vienna</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this prospective randomized controlled multi center trial the investigators stratify &quot;Very&#xD;
      Low Birthweight &quot; (VLBW)-infants with growth retardation in small for gestational age (SGA)&#xD;
      or intrauterine growth restricted (IUGR) - infants and aim to investigate the impact of a&#xD;
      nutritional management with enhanced nutrients from discharge up to the 52nd week of&#xD;
      postconceptional age on growth, body composition, metabolic programming, metabolomics,&#xD;
      microbiome and long term neurodevelopmental outcome. In this study, the investigators will&#xD;
      evaluate the difference in metabolic profiles of SGA and IUGR preterm infants. The&#xD;
      investigators will further longitudinally assess, how different nutritional interventions&#xD;
      affect the altered pathways in the first year of life and identify, in combination with data&#xD;
      available from metabolic markers, microbiome and breast milk analysis, potential pathways&#xD;
      resulting in increased disease risk later in life.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Prematurity is the leading cause for mortality and morbidity in newborns with very low birth&#xD;
      weight (VLBW) infants (&lt; 1500g birth weight) at highest risk. Ten to thirty percent of VLBW&#xD;
      infants are also born too small for their gestational age defined by a birth weight below the&#xD;
      10th percentile. In daily neonatal intensive care, consequential long term-follow up and most&#xD;
      studies all growth restricted premature infants are treated the same, importantly this&#xD;
      includes the nutritional management after birth. However, different groups of patients with&#xD;
      different causal pathologies are subsumed under the definition growth restriction or born too&#xD;
      small. One group of growth restricted patients refers to the infants born constitutionally&#xD;
      small or small for gestational age (SGA). The other group refers to infants with an&#xD;
      intrauterine growth restriction (IUGR) caused by a complex antenatal pathology. Consequently,&#xD;
      the nutritional management after birth is very important to minimize the potential risk for&#xD;
      developing obesity, diabetes and cardiovascular diseases later in life and to achieve optimal&#xD;
      growth. So far we do not consider the different underlying pathomechanisms of growth&#xD;
      restriction in our nutritional concepts for preterm infants and therefore cause long-term&#xD;
      consequences. The European society of pediatric gastroenterology, hematology and nutrition&#xD;
      (ESPGHAN) recommends to feed enhanced nutrients up to 52nd week of gestation in all growth&#xD;
      restricted preterm infants- regardless if they are SGA or IUGR premature. Actually, reliable&#xD;
      data guaranteeing that the recommended &quot;enhanced nutrients strategy&quot; providing extra&#xD;
      nutrients up to 52 weeks for SGA and IUGR infants is safe and effective for both groups in&#xD;
      terms of long-term growth and metabolic programming are lacking.&#xD;
&#xD;
      A total of 348 preterm infants born and discharged below the 10th percentile at term will be&#xD;
      included in the study and stratified according to SGA or IUGR by a combination of antenatal&#xD;
      ultrasound parameters and growth parameters (including 10% screening failures and 20% drop&#xD;
      out. Furthermore IUGR and SGA growth restricted preterm infants will be stratified according&#xD;
      to breastfeeding or formula feeding and randomized in one of the following groups: Standard&#xD;
      nutrients group (breastfeeding or starter formula) or Enhanced nutrients group (fortified&#xD;
      breast milk or post-discharge formula. Body composition measurements will be performed by air&#xD;
      displacement plethysmography - a non-invasive method. Anthropometric measurements will be&#xD;
      performed by measuring weight, height and head circumference. Furthermore, parameters of&#xD;
      metabolic programming, metabolomics, the stool microbiome and neurodevelopmental outcome will&#xD;
      be determined. Additionally, the stool microbiome will be characterized from infant stool&#xD;
      samples and compared between the two groups. After an interventional period of three months&#xD;
      infants will be followed up until 2 years of age.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    no funding&#xD;
  </why_stopped>
  <start_date type="Anticipated">March 2019</start_date>
  <completion_date type="Anticipated">January 2022</completion_date>
  <primary_completion_date type="Anticipated">January 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Fat Free Mass</measure>
    <time_frame>3 months</time_frame>
    <description>Fat free mass measured by body plethysmography</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>anthropometry-length</measure>
    <time_frame>24 months</time_frame>
    <description>length in cm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>anthropometry-weight</measure>
    <time_frame>24 months</time_frame>
    <description>weight in grams</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>anthropometry-HC</measure>
    <time_frame>24 months</time_frame>
    <description>head circumference in cm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>anthropometry-z-score</measure>
    <time_frame>24 months</time_frame>
    <description>z-scores</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>parameters of metabolic programming- IGF1</measure>
    <time_frame>12 months</time_frame>
    <description>IGF-1in ng/ml</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>parameters of metabolic programming-IGF3</measure>
    <time_frame>12 months</time_frame>
    <description>IGF-3 in ng/ml</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>parameters of metabolic programming-IGF-BP</measure>
    <time_frame>12 months</time_frame>
    <description>IGF-BP in ng/ml</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>parameters of metabolic programming-Leptin</measure>
    <time_frame>12 months</time_frame>
    <description>Leptin in ng/ml</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>parameters of metabolic programming-Adiponectin</measure>
    <time_frame>12 months</time_frame>
    <description>Adiponectin in mcg/ml</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>neurodevelopmental outcome</measure>
    <time_frame>24months</time_frame>
    <description>Bayley scales</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>metabolomics</measure>
    <time_frame>12 months</time_frame>
    <description>Metabolomic analysis will determine around 200 metabolites covering polar lipids (SOFIA), acylcarnitines (CARN), non-esterified fatty acids (NEFA) and amino acids (AA). Data will be acquired according to retention time and mass transition on triple quadrupole mass spectrometer, controlled by Analyst.&#xD;
All metabolite concentrations are reported in µmol/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>stool microbiome</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>macronutrients in breastmilk-fat</measure>
    <time_frame>6 months</time_frame>
    <description>Fat will be analysed by modified Mojonnierether extraction (g/100ml)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>macronutrients in breastmilk-Lactose</measure>
    <time_frame>6 months</time_frame>
    <description>Lactose will be determined by Lactose analysis method: LC-MS/MS (g/100ml)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>macronutrients in breastmilk-protein</measure>
    <time_frame>6 months</time_frame>
    <description>Protein will be determined by elemental analysis (g/100ml)</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Growth Failure</condition>
  <condition>Adiposity</condition>
  <condition>Diabetes</condition>
  <condition>Neurologic Deficits</condition>
  <arm_group>
    <arm_group_label>SGA-enhanced nutrients</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Infants will receive fortified breast milk (&gt;50% meals/d fortified, 1,4 g protein, 85 kcal/100ml, FM85, Nestle ®) or post discharge formula (2g protein; 73-75 kcal/100ml; Aptamil PDF, Milupa® or Beba F Nestle® ) between discharge and 52nd week of gestation (three months after term)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SGA-standard nutrients</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Infants will receive unfortified breast milk (65-70kcal/100ml) or starter formula (1,2- 1,3g protein, 66 kcal/100ml Beba Pre Pro Start, Nestle® or Aptamil Pre, Milupa ®) between discharge and 52nd week of gestation (three months after term).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IUGR-enhanced nutrients</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Infants will receive fortified breast milk (&gt;50% meals/d fortified, 1,4 g protein, 85 kcal/100ml, FM85, Nestle ®) or post discharge formula (2g protein; 73-75 kcal/100ml; Aptamil PDF, Milupa® or Beba F Nestle® ) between discharge and 52nd week of gestation (three months after term</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IUGR-standard nutrients</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Infants will receive unfortified breast milk (65-70kcal/100ml) or starter formula (1,2- 1,3g protein, 66 kcal/100ml Beba Pre Pro Start, Nestle® or Aptamil Pre, Milupa ®) between discharge and 52nd week of gestation (three months after term).</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>SGA-enhanced nutrients</intervention_name>
    <description>Infants will receive fortified breast milk (&gt;50% meals/d fortified, 1,4 g protein, 85 kcal/100ml, FM85, Nestle ®) or post discharge formula (2g protein; 73-75 kcal/100ml; Aptamil PDF, Milupa® or Beba F Nestle® ) between discharge and 52nd week of gestation (three months after term</description>
    <arm_group_label>SGA-enhanced nutrients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>IUGR-enhanced nutrients</intervention_name>
    <description>Infants will receive fortified breast milk (&gt;50% meals/d fortified, 1,4 g protein, 85 kcal/100ml, FM85, Nestle ®) or post discharge formula (2g protein; 73-75 kcal/100ml; Aptamil PDF, Milupa® or Beba F Nestle® ) between discharge and 52nd week of gestation (three months after term</description>
    <arm_group_label>IUGR-enhanced nutrients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>SGA-standard nutrients</intervention_name>
    <description>Infants will receive unfortified breast milk (65-70kcal/100ml) or starter formula (1,2- 1,3g protein, 66 kcal/100ml Beba Pre Pro Start, Nestle® or Aptamil Pre, Milupa ®) between discharge and 52nd week of gestation (three months after term)</description>
    <arm_group_label>SGA-standard nutrients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>IUGR-standard nutrients</intervention_name>
    <description>Infants will receive unfortified breast milk (65-70kcal/100ml) or starter formula (1,2- 1,3g protein, 66 kcal/100ml Beba Pre Pro Start, Nestle® or Aptamil Pre, Milupa ®) between discharge and 52nd week of gestation (three months after term)</description>
    <arm_group_label>IUGR-standard nutrients</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Preterm infants with a birth weight &lt;1500g and birth weight &lt;10th percentile.&#xD;
&#xD;
          -  Weight at term &lt;10th percentile&#xD;
&#xD;
          -  Informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Genetic or metabolic diseases with the primary effect on growth&#xD;
&#xD;
          -  Necrotizing enterocolitis&#xD;
&#xD;
          -  Intraventricular hemorrhage (IVH) &gt;Grade II&#xD;
&#xD;
          -  Periventricular leukomalacia (PVL) Stage III&#xD;
&#xD;
          -  Genetic or metabolic disorders&#xD;
&#xD;
          -  Bronchopulmonary dysplasia&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>42 Weeks</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nadja Haiden, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>MUW</affiliation>
  </overall_official>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>December 5, 2016</study_first_submitted>
  <study_first_submitted_qc>December 17, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 21, 2016</study_first_posted>
  <last_update_submitted>March 19, 2019</last_update_submitted>
  <last_update_submitted_qc>March 19, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 21, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Medical University of Vienna</investigator_affiliation>
    <investigator_full_name>Nadja Haiden,MD</investigator_full_name>
    <investigator_title>Assoc. Prof. Dr.</investigator_title>
  </responsible_party>
  <keyword>preterm infants</keyword>
  <keyword>SGA infants</keyword>
  <keyword>IUGR infants</keyword>
  <keyword>growth</keyword>
  <keyword>body composition</keyword>
  <keyword>metabolomics</keyword>
  <keyword>microbiome</keyword>
  <keyword>adiposity markers</keyword>
  <keyword>metabolic programming</keyword>
  <keyword>neurodevelopmental outcome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neurologic Manifestations</mesh_term>
    <mesh_term>Obesity</mesh_term>
    <mesh_term>Failure to Thrive</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

